About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)

NCT00383214·60 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

UCB Pharma

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

+ANA at screening
BILAG Index B Level Activity in at least 2 body systems/organs
Has SLE by ACR revised criteria (meets,\<4 criteria)

You may not be if

Active Severe Lupus as defined by BILAG Index Level A in any body system or organ.
Allergy to human antibodies or Murine.

The record

StatusTerminated

PhasePhase 3

Taking part54

StartedMay 2005

UpdatedJun 7, 2012

Conditions

Systemic Lupus Erythematosus

Where60

Birmingham, Alabama, United States
Tucson, Arizona, United States
Los Angeles, California, United States

Clareo Health | Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)